{"changeSha256":"6d815124f25365059a402b72dd427f14de26c5005691aba40b1afe22ef162fb6","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Vyleesi for HSDD in premenopausal women","before":"U.S. label record","field":"Status"},{"after":"A melanocortin receptor agonist approved by FDA as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.","before":"A melanocortin receptor agonist peptide. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.","before":"The cited DailyMed label identifies Bremelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54, fda-vyleesi-s005-approval-2026","before":"dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-bremelanotide-identity","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]; U.S. Food and Drug Administration [sources: fda-drugs-nda210557-2019-06-21-d4c7e45d4a54]","before":"U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]","field":"Named organizations"},{"after":"name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1, fda-drugs-nda210557-2019-06-21-d4c7e45d4a54; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1","before":"name: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; aliases: fda-bremelanotide-identity; category: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; status: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; summary: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1; evidenceNote: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/bremelanotide/versions/4/","version":4},"id":"profile:bremelanotide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Vyleesi label, and added the Drugs@FDA approval record and FDA’s October 22, 2026 approval of a labeling supplement.","peptideSlugs":["bremelanotide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/bremelanotide/v3.json","sha256":"a7672b1f2ad4695f7b280ce5d1ac2be5e6e30fc887f4d4936a34e8e419b67bc7"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/bremelanotide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf&version=1","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda210557-2019-06-21-d4c7e45d4a54","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA210557 · original submission status AP · 2019-06-21 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA210557%22&limit=1","verifiedAt":"2026-08-14"},{"id":"fda-vyleesi-s005-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Vyleesi (bremelanotide): NDA 210557 supplement S-005 approval letter, October 22, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/210557Orig1s005ltr.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"bremelanotide","type":"profile"}}
